Assessing the effects of National Health Insurance reimbursement policy revisions for anti-osteoporotic drugs in Korean women aged 50 or older
暂无分享,去创建一个
S. Moon | Sohee Park | Hankil Lee | Y. Yu | Hye-Young Kang | Ja Seo Koo
[1] G. Romero. Abstract #300092: The Triglyceride Paradox in Patients Hospitalized for Acute Myocardial Infarction , 2020 .
[2] N. Watts,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[3] D. Kiel,et al. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] M. Bouxsein,et al. Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. , 2019, Endocrine reviews.
[5] L. Williams,et al. Do reductions in out-of-pocket expenses for dual energy X-ray absorptiometry scans translate to reduced fracture incidence amongst older Australians? A population-based study , 2018, Archives of Osteoporosis.
[6] S. Cummings,et al. The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] Sung Jae Kim,et al. Incidence and Seasonal Variation of Distal Radius Fractures in Korea: a Population-based Study , 2018, Journal of Korean medical science.
[8] D. Bauer,et al. Managing Osteoporosis in Patients on Long‐Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] Soo-Hong Han,et al. Epidemiology and Seasonal Variance of Incidence of Distal Radius Fractures , 2015 .
[10] Tae Hyun Kim,et al. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea , 2015, BMJ Open.
[11] Christine Y. Lu,et al. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. , 2014, Health policy.
[12] G. Hawker,et al. Impact of a change in physician reimbursement on bone mineral density testing in Ontario, Canada: a population-based study. , 2014, CMAJ open.
[13] W. Leslie,et al. Examining the impact of reimbursement on referral to bone density testing for older adults: 8 years of data from the Barwon Statistical Division, Australia , 2013, Archives of Osteoporosis.
[14] Young-Kyun Lee,et al. Epidemiology of Osteoporosis and Osteoporotic Fractures in South Korea , 2013, Endocrinology and metabolism.
[15] M. Brandi,et al. Epidemiology of Osteoporosis and Fragility Fractures , 2013 .
[16] S. Cummings,et al. The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] L. Levin,et al. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. , 2012, Health policy.
[18] Y. Ha,et al. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea , 2011, Journal of Bone and Mineral Metabolism.
[19] Chan Mi Park,et al. Burden of osteoporosis in adults in Korea: a national health insurance database study , 2011, Journal of Bone and Mineral Metabolism.
[20] H. Choi,et al. Medical Service Utilization with Osteoporosis , 2010 .
[21] Chun ChangBae,et al. Republic of Korea Health system review , 2009 .
[22] Shin-Yoon Kim,et al. Treatment of Osteoporosis after Hip Fractures in Patients Older than 50 Years , 2007 .
[23] S. Cummings,et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.
[24] A K Wagner,et al. Segmented regression analysis of interrupted time series studies in medication use research , 2002, Journal of clinical pharmacy and therapeutics.
[25] N. Ghannam,et al. Book review: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. , 1994, Annals of Saudi medicine.